Results 201 to 210 of about 99,788 (345)

Mucous Membrane Pemphigoid After Anti‐PD‐1 Therapy: Risk‐Stratified Management and Treatment Outcomes

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Mucous membrane pemphigoid (MMP) following anti‐programmed cell death‐1 (PD‐1) therapy is rare but increasingly reported. Management of high‐ and low‐risk MMP in this setting and the potential oncologic trade‐offs remain poorly defined. We performed a narrative synthesis of all published cases of anti‐PD‐1‐associated MMP, following MEDLINE ...
Serena Dienes   +2 more
wiley   +1 more source

Review and comparison of body sites among patients with cutaneous malignant melanoma: an observational study. [PDF]

open access: yesIr J Med Sci, 2023
Wolinska A   +6 more
europepmc   +1 more source

Cutaneous Leiomyosarcoma of the Skin: An Updated Review of Epidemiology, Pathogenesis, and Management

open access: yesInternational Journal of Dermatology, EarlyView.
This review provides an update on the epidemiology, pathogenesis, and clinical/histologic features of cutaneous leiomyosarcoma. Prognostic factors (e.g., depth of tumor involvement, grade, etc.) that can facilitate risk stratification are also discussed, as are treatment approaches for this rare malignancy.
Tejas P. Joshi   +4 more
wiley   +1 more source

Tissue Resident Memory Cells: Friend or Foe?

open access: yesImmunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude   +2 more
wiley   +1 more source

Histopathological evaluation of cutaneous malignant melanoma: A retrospective study. [PDF]

open access: yesExp Ther Med, 2022
Gheoca Mutu DE   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy